FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096840629> ?p ?o ?g. }

• W3096840629 endingPage "18" @default.
• W3096840629 startingPage "17" @default.
• W3096840629 abstract "Introduction: Allogeneic hematopoietic stem cell transplant (allo-HCT) is a potential curative therapy for a variety of both malignant and nonmalignant hematologic disorders. However, allo-HCT is costly and requires highly specialized, technologically advanced care that is only available in select healthcare centers across the country. Due to its cost and limited availability, minority populations are at risk for healthcare disparities in access to and outcomes of allo-HCT. Prior studies have focused on the impact of health disparities, including race, and geographic residence at time of transplant, on allo-HCT outcomes with variable results. The aim of this study was to evaluate the impact of race and location of residence on outcomes of allo-HCT at one major referral institution. Methods: We performed a retrospective cohort study of patients that underwent allo-HCT at the Ohio State University from 1984 to 2018. The impact of demographic factors including race and place of primary residence were assessed. Patients were divided into race defined as Caucasian, African American (AA), and other. They were also grouped by zip code into rural, suburban, and urban groups. Rural was defined as less than 1000 people per square mile, suburban between 1000-3000 people per square mile, and urban greater than 3000 people per square mile. 2018 population estimates were used. Patients were then stratified into 7 groups based on year (yr) of transplant for analysis. Group (gp) 1 included 1984-1988, gp 2 1989-1993, gp 3 1994-1998, gp 4 1999-2003, gp 5 2004-2008, gp 6 2009-2013, and gp 7 2014-2018. Primary endpoints were progression free survival (PFS) and overall survival (OS). PFS and OS were calculated using Kaplan Meier Curves and compared using log-rank test between race and residence groups. Results: A total of 1,943 patients were included in the study. Of these patients, median age at time of transplant was 50 years old (range 18-76), and 59.6% were male. AML/MDS patients made up the majority of the cohort at 46.3%, with the other most common diagnoses being non-Hodgkin's lymphoma (14.2%), acute lymphocytic leukemia (11.8%), and chronic myeloid leukemia (10.1%). Most patients (94.3%) identified as Caucasian, while 4.6% identified as AA, and 1.1% other. The majority of patients lived in a rural area at the time of transplant with 63.4% rural, 22.9% suburban, and 13.8% urban. There was no significant difference in OS or PFS between Caucasian and AA patients (Figure 1A and B; p=0.15, 0.21). Median OS for AA was 1.9 yrs [95% confidence interval (CI): 0.8-3.6] as compared to 2.3 yrs (95% CI: 1.9-2.9) for Caucasians, with 5 -yr OS of 33 vs. 42% and 10-yr OS of 21 vs. 36% for AA and Caucasian, respectively. Median PFS was 0.9 (95% CI: 0.5-2.7) and 1.3 yrs (95% CI 1.1-1.6), with 5 -yr PFS of 30 vs. 37% and 10-yr PFS of 21 vs. 32% for AA and Caucasian, respectively. There also was no significant difference in OS or PFS between rural, urban, and suburban patients (Figure 2A and 2B; p=0.39, 0.17), with median OS in the three groups 2.2 (95%CI: 1.7-2.9), 2.9 (95%CI: 1.6-4.5), and 2.2 (95% CI: 1.6-3.6) yrs, and 5-yr OS of 40 vs. 43 vs. 43% and 10-yr OS of 33 vs. 39 vs. 39%, respectively. Median PFS were 2.2 (95%CI: 1.7-2.9), 2.9 (95%CI: 1.6-4.5), and 2.2 yrs [95% CI: 1.6-3.6], with 5-yr PFS of 36 vs. 40 vs. 38% and 10-yr PFS of 30 vs. 37 vs. 35%, respectively. Conclusion: Our study suggests that once patients undergo allo-HCT, there is no significant difference in outcomes between patients based on race or residence. This finding suggests that while these underserved populations may initially have less access to specialized care for HCT, if they ultimately undergo allo-HCT, outcomes are similar to their counterparts. Our study did show a significantly lower rates of allo-HCT performed in non-Caucasian races (94% Caucasians vs 4.6% AA and 1% other), which may reflect disparities in access to care in these groups as well as a lack of donors. Further research is needed to assess the barriers for these underserved patients to undergo transplant and to help ameliorate these barriers. Disclosures Chaudhry: Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees. Bumma:Amgen: Speakers Bureau; Sanofi: Speakers Bureau. Khan:Amgen: Consultancy; Janssen: Consultancy. Devarakonda:Janssen: Consultancy. Vasu:Janssen: Membership on an entity's Board of Directors or advisory committees; Omeros: Membership on an entity's Board of Directors or advisory committees; Kiadis Inc: Other: Kiadis has obtained exclusive licensing requirements from The OHio State University. Jaglowski:Kite, a Gilead Company: Consultancy, Research Funding; Juno: Consultancy; Novartis: Consultancy, Research Funding; CRISPR: Consultancy. William:Merck: Research Funding; Celgene: Consultancy, Honoraria; Dova: Research Funding; Seattle Genetics: Research Funding; Incyte: Research Funding; Guidepoint Global: Consultancy; Kyowa Kirin: Consultancy, Honoraria. Mims:Syndax Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Kura Oncology: Membership on an entity's Board of Directors or advisory committees; Leukemia and Lymphoma Society: Other: Senior Medical Director for Beat AML Study; Agios: Consultancy; Novartis: Speakers Bureau; Jazz Pharmaceuticals: Other: Data Safety Monitoring Board. Brammer:Seattle Genetics, Inc.: Speakers Bureau; Celgene Corporation: Research Funding. Efebera:Celgene: Research Funding; Pharmacyclics: Research Funding; Takeda: Honoraria, Speakers Bureau; Ohio State University: Current Employment." @default.
• W3096840629 created "2020-11-09" @default.
• W3096840629 creator A5001346811 @default.
• W3096840629 creator A5003367392 @default.
• W3096840629 creator A5010473913 @default.
• W3096840629 creator A5014248827 @default.
• W3096840629 creator A5019488668 @default.
• W3096840629 creator A5023917898 @default.
• W3096840629 creator A5024996698 @default.
• W3096840629 creator A5026731813 @default.
• W3096840629 creator A5026999256 @default.
• W3096840629 creator A5033734703 @default.
• W3096840629 creator A5035192668 @default.
• W3096840629 creator A5043387663 @default.
• W3096840629 creator A5044663373 @default.
• W3096840629 creator A5046091655 @default.
• W3096840629 creator A5056645750 @default.
• W3096840629 creator A5058362903 @default.
• W3096840629 creator A5060806301 @default.
• W3096840629 creator A5064150576 @default.
• W3096840629 creator A5072835425 @default.
• W3096840629 creator A5073720570 @default.
• W3096840629 creator A5078508615 @default.
• W3096840629 creator A5086380393 @default.
• W3096840629 creator A5090478102 @default.
• W3096840629 date "2020-11-05" @default.
• W3096840629 modified "2023-10-06" @default.
• W3096840629 title "Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant" @default.
• W3096840629 doi "https://doi.org/10.1182/blood-2020-140012" @default.
• W3096840629 hasPublicationYear "2020" @default.
• W3096840629 type Work @default.
• W3096840629 sameAs 3096840629 @default.
• W3096840629 citedByCount "1" @default.
• W3096840629 countsByYear W30968406292022 @default.
• W3096840629 crossrefType "journal-article" @default.
• W3096840629 hasAuthorship W3096840629A5001346811 @default.
• W3096840629 hasAuthorship W3096840629A5003367392 @default.
• W3096840629 hasAuthorship W3096840629A5010473913 @default.
• W3096840629 hasAuthorship W3096840629A5014248827 @default.
• W3096840629 hasAuthorship W3096840629A5019488668 @default.
• W3096840629 hasAuthorship W3096840629A5023917898 @default.
• W3096840629 hasAuthorship W3096840629A5024996698 @default.
• W3096840629 hasAuthorship W3096840629A5026731813 @default.
• W3096840629 hasAuthorship W3096840629A5026999256 @default.
• W3096840629 hasAuthorship W3096840629A5033734703 @default.
• W3096840629 hasAuthorship W3096840629A5035192668 @default.
• W3096840629 hasAuthorship W3096840629A5043387663 @default.
• W3096840629 hasAuthorship W3096840629A5044663373 @default.
• W3096840629 hasAuthorship W3096840629A5046091655 @default.
• W3096840629 hasAuthorship W3096840629A5056645750 @default.
• W3096840629 hasAuthorship W3096840629A5058362903 @default.
• W3096840629 hasAuthorship W3096840629A5060806301 @default.
• W3096840629 hasAuthorship W3096840629A5064150576 @default.
• W3096840629 hasAuthorship W3096840629A5072835425 @default.
• W3096840629 hasAuthorship W3096840629A5073720570 @default.
• W3096840629 hasAuthorship W3096840629A5078508615 @default.
• W3096840629 hasAuthorship W3096840629A5086380393 @default.
• W3096840629 hasAuthorship W3096840629A5090478102 @default.
• W3096840629 hasConcept C126322002 @default.
• W3096840629 hasConcept C144024400 @default.
• W3096840629 hasConcept C149923435 @default.
• W3096840629 hasConcept C167135981 @default.
• W3096840629 hasConcept C2776135927 @default.
• W3096840629 hasConcept C2776269092 @default.
• W3096840629 hasConcept C2908647359 @default.
• W3096840629 hasConcept C2911091166 @default.
• W3096840629 hasConcept C512399662 @default.
• W3096840629 hasConcept C59822182 @default.
• W3096840629 hasConcept C71924100 @default.
• W3096840629 hasConcept C72563966 @default.
• W3096840629 hasConcept C74909509 @default.
• W3096840629 hasConcept C76509639 @default.
• W3096840629 hasConcept C86803240 @default.
• W3096840629 hasConcept C99454951 @default.
• W3096840629 hasConceptScore W3096840629C126322002 @default.
• W3096840629 hasConceptScore W3096840629C144024400 @default.
• W3096840629 hasConceptScore W3096840629C149923435 @default.
• W3096840629 hasConceptScore W3096840629C167135981 @default.
• W3096840629 hasConceptScore W3096840629C2776135927 @default.
• W3096840629 hasConceptScore W3096840629C2776269092 @default.
• W3096840629 hasConceptScore W3096840629C2908647359 @default.
• W3096840629 hasConceptScore W3096840629C2911091166 @default.
• W3096840629 hasConceptScore W3096840629C512399662 @default.
• W3096840629 hasConceptScore W3096840629C59822182 @default.
• W3096840629 hasConceptScore W3096840629C71924100 @default.
• W3096840629 hasConceptScore W3096840629C72563966 @default.
• W3096840629 hasConceptScore W3096840629C74909509 @default.
• W3096840629 hasConceptScore W3096840629C76509639 @default.
• W3096840629 hasConceptScore W3096840629C86803240 @default.
• W3096840629 hasConceptScore W3096840629C99454951 @default.
• W3096840629 hasIssue "Supplement 1" @default.
• W3096840629 hasLocation W30968406291 @default.
• W3096840629 hasOpenAccess W3096840629 @default.
• W3096840629 hasPrimaryLocation W30968406291 @default.
• W3096840629 hasRelatedWork W1972759538 @default.
• W3096840629 hasRelatedWork W1991545591 @default.
• W3096840629 hasRelatedWork W2019140801 @default.
• W3096840629 hasRelatedWork W2094618122 @default.

• next